Clinical trials: Schizophrenia
Schizophrenia
A 6-Week Multicenter Trial Of Varenicline Tartrate For Cognitive Impairment In Subjects With Schizophrenia
The primary objective of this protocol is to assess the efficacy of two dose strengths of varenicline (0.5 mg BID and 1mg BID) as adjunctive treatment for cognitive impairment in symptomatically stable outpatient schizophrenic…
- Trial name
- NCT00743847
- Testing
- varenicline
- Sponsor
- Pfizer
Schizophrenia
PK, Safety, and Tolerability Study of RBP-7000 of Different Molecular Weight Polymer in Subjects With Schizophrenia
Primary Objective: To assess the relative bioavailability of RBP-7000 formulated with 2 different molecular weights (MW) (low and high MW as test treatments) of poly (DL-lactide-co-glycolide) with a carboxylic acid end group…
- Trial name
- NCT02687984
- Testing
- RBP-7000
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- Indivior Inc.
Schizophrenia, Psychotic Disorders
A Study of the Effectiveness and Safety of Risperidone in the Treatment of Adolescents With Schizophrenia
The purpose of the study is to assess the safety and effectiveness of risperidone (an antipsychotic medication) in adolescents with schizophrenia over 6 months of treatment.
- Trial name
- NCT00246285
- Testing
- risperidone
- Volunteers
- 381 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
A Long-term Administration Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Schizophrenia
Confirm the tolerability and safety of long-term administration of the brexpiprazole QW formulation in patients with schizophrenia
- Trial name
- NCT05326347
- Testing
- OPC-34712FUM/ Brexpiprazole fumarate
- Where
- Japan
- Volunteers
- 247 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Schizophrenia and Schizoaffective Disorder
Switch Study of Existing Atypical Antipsychotics to Bifeprunox
The study will evaluate the safety and tolerability of switching subjects with schizophrenia or schizoaffective disorder from their existing antipsychotic medication to Bifeprunox.
- Trial name
- NCT00347425
- Testing
- Aripiprazole, Olanzapine, Risperidone
- Where
- 122 sites in United States, Argentina and 7 more
- Volunteers
- 286 people
- Sponsor
- Solvay Pharmaceuticals
Schizophrenia, Bipolar Disorder
A Drug Interaction Study of Valproic Acid and Paliperidone Extended-Release (ER) in Patients With Schizophrenia, Bipolar I Disorder, or Schizoaffective Disorder
The purpose of this study is to evaluate the potential effect of multiple oral doses of an extended release formulation of paliperidone on the pharmacokinetics (blood levels) of valproic acid (VPA) in patients with schizophrenia…
- Conditions
- Schizophrenia, Bipolar Disorder, Psychotic Disorders
- Trial name
- NCT01094249
- Testing
- divalproex sodium ER/paliperidone ER
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
This is a study in chronic stable Schizophrenia with the purpose to answer the question of whether agonism of the nicotinic alpha7 receptor is capable of enhancing cognition in a well defined chronic stable patient population…
- Trial name
- NCT01730768
- Testing
- AQW051
- Where
- 13 sites in United States
- Volunteers
- 147 people
- Sponsor
- Novartis Pharmaceuticals
Schizophrenia
Intramuscular Injections of Paliperidone Palmitate in the Arm or Buttock of Subjects With Schizophrenia
The purpose of the study is to compare the pharmacokinetic parameters (blood concentrations) of i.m. paliperidone palmitate after administration in 2 different injection sites (deltoid or gluteal).
- Trial name
- NCT00073320
- Testing
- Paliperidone Palmitate
- Volunteers
- 88 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Bipolar Disorder
A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children
The purpose of this study is to evaluate the effects of risperidone compared with other atypical antipsychotic drugs on the physical maturity, growth and development of children, and the risk of prolactin-related adverse events…
- Conditions
- Schizophrenia, Bipolar Disorder, Autistic Disorder, Conduct and Other Disruptive Behavior Disorders
- Trial name
- NCT01050582
- Testing
- Risperidone, Other atypical antipsychotic drugs
- Where
- 28 sites in United States, Belgium and 4 more
- Volunteers
- 244 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Study on Metabolic Parameters of Sertindole in Patients With Schizophrenia
The purpose of this exploratory study is to evaluate the effects of sertindole and olanzapine on metabolic parameters and syndrome in patients with schizophrenia.
- Trial name
- NCT00759460
- Testing
- Sertindole, Olanzapine
- Where
- China
- Volunteers
- 250 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia, Schizophreniform Disorder
An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective Disorders
The purpose of this study is to evaluate the efficacy and safety of long acting injectable microspheres of risperidone in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment…
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
- Trial name
- NCT01855074
- Testing
- Risperidone
- Volunteers
- 80 people
- Sponsor
- Janssen-Cilag Ltd.
Schizophrenia
Flexible-dose Long-term Extension Study of Lu AF11167 in Patients With Schizophrenia With Prominent Negative Symptoms
A study to evaluate the long-term safety and tolerability of flexible doses of Lu AF11167 in patients with schizophrenia during the 24-week treatment period
- Trial name
- NCT03929497
- Testing
- Lu AF11167
- Where
- 30 sites in Bulgaria, Estonia and 5 more
- Volunteers
- 96 people
- Sponsor
- H. Lundbeck A/S
Bipolar Disorder, Affective Disorders, Psychotic
A Study to Evaluate the Safety and Effectiveness of Topiramate Compared to Placebo in the Treatment of Patients With Bipolar I Disorder
The purpose of this study is to determine the safety and efficacy of topiramate in adolescents with manic or mixed episodes of Bipolar I Disorder.
- Conditions
- Bipolar Disorder, Affective Disorders, Psychotic, Mood Disorders, Mental Disorders
- Trial name
- NCT00035802
- Testing
- Topiramate
- Volunteers
- 13 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
This is a Phase 3, randomized, double blind, placebo controlled, fixed dose, study designed to evaluate the efficacy, safety, tolerability, and of LB-102 versus placebo for the treatment of adult patients with an acute…
- Trial name
- NOVA2 (NCT07363577)
- Testing
- LB-102 (50 mg tablet), LB-102 (100 mg tablet)
- Where
- 13 sites in United States
- Volunteers
- 456 people
- Sponsor
- LB Pharmaceuticals Inc.
Schizophrenia
A Physical Dependence Study in Schizophrenia
The purpose of this study is to determine whether or not people with schizophrenia who take LY2140023 become physically dependent on it, and experience a series of symptoms such as craving to have the drug when they stop using…
- Trial name
- NCT01452919
- Testing
- LY2140023
- Where
- 10 sites in United States, Greece
- Volunteers
- 123 people
- Sponsor
- Denovo Biopharma LLC
Schizophrenia, Psychotic Disorders
Kahn Study; Investigation Of The Efficacy Of Ziprasidone Versus Olanzapine In The Management Of Recent-Onset Psychosis; A Flexible-Dose, Parallel Group, Double-Blind Study
This study intends to compare novel antipsychotics ziprasidone and olanzapine, to confirm the findings of an open study -where stable patients receiving olanzapine switched to ziprasidone- which showed maintenance of clinical…
- Trial name
- NCT00145444
- Testing
- olanzapine, ziprasidone
- Where
- 7 sites in Belgium, Netherlands
- Volunteers
- 100 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia or Schizoaffective
Safety, Tolerability, and Pharmacokinetics of Lumateperone Long-Acting Injectable Formulations in Patients With Schizophrenia or Schizoaffective Disorder
Study ITI-007-037 is a Phase 1b, open-label study to evaluate the safety, tolerability, and PK of lumateperone long-acting injectable (LAI) formulations after a single intramuscular injection in patients with stale schizophrenia…
- Trial name
- NCT06627413
- Testing
- Lumateperone Capsule, Lumateperone LAI
- Where
- 4 sites in United States
- Volunteers
- 52 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Schizophrenia
NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.
- Trial name
- NCT06963034
- Testing
- NBI-1117568
- Where
- 21 sites in United States
- Volunteers
- 284 people
- Sponsor
- Neurocrine Biosciences
Schizophrenia
A Study to Investigate Pharmacokinetics, Safety, and Tolerability of B2227 Extended-Release Injectable Suspension and Vraylar® in Participants With Schizophrenia
The study is to evaluate the pharmacokinetic profile of B2227 Extended-Release Injectable Suspension against Vraylar® Cariprazine capsules of AbbVie Inc. in participants with schizophrenia.
- Trial name
- NCT07722728
- Testing
- 30 mg B2227, 70 mg B2227, 150 mg B2227
- Volunteers
- 84 people
- Sponsor
- Bostal Drug Delivery Co., Ltd
Schizophrenia, Bipolar I Disorder
ERG Components in Schizophrenia and Bipolar Disorder Type I
This study will further assess ERG components obtained with different ERG devices, to be considered in a prediction model for each diagnosis.
- Trial name
- NCT03788811
- Testing
- ERG assessment (RSPA)
- Where
- 19 sites in United States, Australia and 1 more
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- diaMentis Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.